Quantification of Lung PET Images: Challenges and Opportunities

• Published in: Journal of Nuclear Medicine Vol. 58; no. 2; pp. 201 - 207
• Main Authors: Chen, Delphine L., Cheriyan, Joseph, Chilvers, Edwin R., Choudhury, Gourab, Coello, Christopher, Connell, Martin, Fisk, Marie, Groves, Ashley M., Gunn, Roger N., Holman, Beverley F., Hutton, Brian F., Lee, Sarah, MacNee, William, Mohan, Divya, Parr, David, Subramanian, Deepak, Tal-Singer, Ruth, Thielemans, Kris, van Beek, Edwin J.R., Vass, Laurence, Wellen, Jeremy W., Wilkinson, Ian, Wilson, Frederick J.
• Format: Journal Article
• Language: English
• Published: United States Society of Nuclear Medicine 01.02.2017
• Subjects: Continuing Education; Fluorodeoxyglucose F18; Global health; Humans; Image Interpretation, Computer-Assisted - methods; Knowledge; Lung - diagnostic imaging; Lung Diseases - diagnostic imaging; Medical treatment; Nuclear medicine; Positron-Emission Tomography - methods; Radiopharmaceuticals; Reproducibility of Results; Respiratory diseases; Respiratory Function Tests - methods; Sensitivity and Specificity; pulmonary; molecular imaging; positron emission tomography; lung inflammation
• DOI: 10.2967/jnumed.116.184796
• ISSN: 0161-5505; 1535-5667

Millions of people are affected by respiratory diseases, leading to a significant health burden globally. Because of the current insufficient knowledge of the underlying mechanisms that lead to the development and progression of respiratory diseases, treatment options remain limited. To overcome this limitation and understand the associated molecular changes, noninvasive imaging techniques such as PET and SPECT have been explored for biomarker development, with F-FDG PET imaging being the most studied. The quantification of pulmonary molecular imaging data remains challenging because of variations in tissue, air, blood, and water fractions within the lungs. The proportions of these components further differ depending on the lung disease. Therefore, different quantification approaches have been proposed to address these variabilities. However, no standardized approach has been developed to date. This article reviews the data evaluating F-FDG PET quantification approaches in lung diseases, focusing on methods to account for variations in lung components and the interpretation of the derived parameters. The diseases reviewed include acute respiratory distress syndrome, chronic obstructive pulmonary disease, and interstitial lung diseases such as idiopathic pulmonary fibrosis. Based on review of prior literature, ongoing research, and discussions among the authors, suggested considerations are presented to assist with the interpretation of the derived parameters from these approaches and the design of future studies.